Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

Thermo Scientific Selected to Supply Maybridge Fragment Library for Key Research

Published: Tuesday, February 05, 2013
Last Updated: Monday, February 04, 2013
Bookmark and Share
Recommended for use by renowned fragment library design expert.

Thermo Fisher Scientific Inc. has been selected to supply compounds from its Maybridge Ro3 2500 Diversity Fragment Library to a leading fragment-based drug discovery firm based in the Netherlands.

ZoBio, a spin-off of Leiden University, focuses on the development and commercialization of biophysical technologies that enable new approaches to drug development and selected the Maybridge fragment library on the recommendation of Dr. Edward Zartler, CEO of Quantum Tessera Consulting LLC.

Dr. Zartler was consulted to identify and purchase the most suitable targeted screening library for ZoBio’s structure-based discovery needs, selecting the Thermo Fisher library for its broad range of pharmacophores.

With more than 10 years of experience in the pharmaceutical industry, Dr. Zartler is an internationally recognized expert in fragment-based drug discovery and editor of the book, “Fragment Based Drug Discovery: A Practical Approach.”

He evaluated several options before selecting the Maybridge collection.

ZoBio has begun using the Maybridge library to design its own compound collection targeted to an epigenetic drug target. The collection will enable ZoBio’s customers to pursue and expedite fragment-based drug delivery.

“The entire Maybridge 2500 collection is Rule of Three (Ro3)-compliant and exceptionally well-curated with greater than 95 percent purity assurance and guaranteed solubility of 1 mM in aqueous phosphate buffer solution,” said Dr. Zartler.

Dr. Zartler continued, “ZoBio assembled its 250 fragment library by virtually screening against a pharmacophore model. It was easy to triage and accept molecules because Maybridge has already done a tremendous job of removing chemically suspect molecules. The breadth of chemical diversity and the depth of compounds to choose from allowed them to rapidly put together a robust, diverse and structure activity relationship-compliant library.”

Maybridge compounds are ideal for development beyond the initial screening assay. Of the approximately 400,000 pharmacophores in the World Drug Index, 87 percent are expressed by the Maybridge Ro3 2500 diversity fragment library.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Biodesign Institute, Thermo Fisher Partner on $9M Radiation Test
Partnership enters a new, $9M phase of a project to produce a diagnostic test to rapidly measure an individual’s level of absorption of ionizing radiation.
Wednesday, June 04, 2014
Thermo, Nuclea Biotechnologies Collaborate to Develop Diabetes Markers
Companies pooling their expertise to develop novel multiplexed research methods for high-throughput quantification of native insulin and its therapeutic analogs.
Monday, June 02, 2014
Thermo Fisher Scientific Announces 4th Annual Cellome Award Winner
Vishal Deshmukh, Scripps Institute to accept award for excellence in the application of high content technology in Multiple Sclerosis research.
Wednesday, February 26, 2014
Thermo Reports 6% Q4 Revenue Growth
Thermo Fisher Scientific Inc. reported its financial results for the fourth quarter and full year ended December 31, 2013.
Friday, January 31, 2014
One Lambda Receives CE Mark Approval for C1qScreen
Assay cited in New England Journal of Medicine for use in determining impact on kidney graft survival.
Tuesday, November 19, 2013
Record Revenues for Thermo Fisher Scientific
Revenue for the quarter grew 6% to $3.26 billion in 2012, versus $3.09 billion in 2011.
Thursday, January 31, 2013
Thermo Scientific Enters into a Long-Term Agreement with Fujirebio
Combination of Thermo Scientific B•R•A•H•M•S PCT assay and Lumipulse platforms to test patients suspected of having sepsis.
Thursday, November 22, 2012
Thermo Fisher Scientific Announces Application Deadlines for Life Sciences Scholarships
Thermo Scientific Pierce Scholarship Winter/Spring semester applications due December 14, 2012.
Wednesday, November 14, 2012
Thermo Fisher Scientific Introduces Guide to Good Washing Practice
The online guide is designed to provide detailed guidance on obtaining secure and reliable performance with every use of the Thermo Scientific Wellwash microplate washers.
Thursday, October 21, 2010
Thermo Fisher Scientific Launches Maybridge Ro3 Diversity Fragment Library
Diverse set of 1,500 molecules engineered for high-quality fragment screening-based programmes.
Tuesday, July 06, 2010
Thermo Fisher Scientific Names Recipients of RNAi Discovery Grants
More than $400,000 in RNAi screening tools awarded to advance biomedical research and drug discovery.
Friday, November 06, 2009
Thermo Fisher Scientific Signs Agreement to Acquire B.R.A.H.M.S. AG
Company acquires provider of specialty in-vitro diagnostic tests for $470 million USD.
Monday, September 07, 2009
Thermo Fisher Scientific to Showcase Innovative Mass Spectrometry Solutions at IMSC 2009
Company will showcase a variety of mass spectrometry software and hardware solutions to deliver improved analytical performance.
Monday, September 07, 2009
Thermo Fisher Scientific Implements LIMS for the Food and Environment Research Agency
Fera uses Thermo Scientific Nautilus to manage critical laboratory data and processes.
Thursday, September 03, 2009
Thermo Fisher Scientific Goes Global with Food Safety Seminar Series
The global seminar program will take place across the U.S., Canada, Europe, Southeast Asia and Japan to explore global perspectives on food safety.
Friday, August 28, 2009
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Potential Persistent Tuberculosis Treatment
Researchers have discovered several first-in-class compounds that target hidden TB infections by attacking a critical process the bacteria use to survive in the hostile environment of the lungs.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
The Do’s and Don’ts of SPR Experiments
Surface Plasmon Resonance (SPR) is a technique that is becoming more widely used, particularly by anyone who wants to obtain accurate on (association) and off (dissociation) rates for biomolecular binding.
Long-Sought Protein Sensor for the ‘Sixth Sense’ Discovered
In a study led by scientists from The Scripps Research Institute (TSRI)the sensor protein for propioception has been identified.
New Anti-Malarial Drug Screening Model
University of South Florida researchers demonstrate novel chemogenomic profiling to identify drug targets for the most lethal strain of malaria.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.
New, Better Test for Prostate Cancer
A study from Karolinska Institutet shows that a new test for prostate cancer is better at detecting aggressive cancer than PSA.
Giant Molecules Inhibit Ebola Infection
European researchers have designed a "giant" molecule formed by thirteen fullerenes covered by carbohydrates which, by blocking this receptor, are able to inhibit the cell infection by an artificial ebola virus model.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos